Experience with the high-intensity sweetener saccharin impairs glucose homeostasis and GLP-1 release in rats

Behavioural Brain Research

Volumn 233, Issue 1, 2012, Pages 1-14

  Swithers, Susan E ^a   Laboy, Alycia F ^a   Clark, Kiely ^a   Cooper, Stephanie ^a   Davidson, T L ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Artificial sweetener; Energy balance; Glucose tolerance; Learning

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; SACCHARIN; YOGHURT;

ANIMAL EXPERIMENT; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENERGY BALANCE; EXPOSURE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE RELEASE; HORMONE RESPONSE; INSULIN RELEASE; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RAT; SATIETY; SWEETNESS; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CONDITIONING, OPERANT; DIETARY SUPPLEMENTS; FOOD DEPRIVATION; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; INSULIN; MALE; RATS; RATS, SPRAGUE-DAWLEY; SACCHARIN; SWEETENING AGENTS;

EID: 84861619861     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.04.024     Document Type: Article

References (81)

1. Davidson T.L., Swithers S.E. A Pavlovian approach to the problem of obesity. International Journal of Obesity & Related Metabolic Disorders 2004, 28:933-935.
2. Swithers S.E., Davidson T.L. A role for sweet taste: calorie predictive relations in energy regulation by rats. Behavioral Neuroscience 2008, 122:161-173.
3. Swithers S.E., Baker C.R., Davidson T.L. General and persistent effects of high-intensity sweeteners on body weight gain and caloric compensation in rats. Behavioral Neuroscience 2009, 123:772-780.
4. Swithers S.E., Martin A.A., Clark K.M., Laboy A.F., Davidson T.L. Body weight gain in rats consuming sweetened liquids. Effects of caffeine and diet composition. Appetite 2010, 55:528-533.
5. Swithers S.E., Martin A.A., Davidson T.L. High-intensity sweeteners and energy balance. Physiology & Behavior 2010, 100:55-62.
6. Rescorla R.A., Wagner A.R. A theory of Pavlovian conditioning: variations in the effectiveness of reinforcement and nonreinforcement. Classical conditioning II: current research and theory 1972, 64-99. Appleton Century Crofts, New York. A.H. Black, W.F. Prokasy (Eds.).
7. Urushihara K., Miller R.R. Stimulus competition between a discrete cue and a training contex: cue competition does not result from the division of a limited resource. Journal of Experimental Psychology: Animal Behavior Processes 2009, 35:197-211.
8. Wagner A.R. Stimulus validity and stimulus selection in associative learning. Fundamental issues in associative learning 1969, 90-122. Dalhousie University Press, Halifax. N.J. Mackintosh, W.K. Honing (Eds.).
9. Davidson T.L., Martin A.A., Clark K., Swithers S.E. Intake of high-intensity sweeteners alters the ability of sweet taste to signal caloric consequences: implications for the learned control of energy and body weight regulation. The Quarterly Journal of Experimental Psychology (Hove) 2011, 64:1430-1441.
10. Swithers S.E., Ogden S.B., Davidson T.L. Fat substitutes promote weight gain in rats consuming high-fat diets. Behavioral Neuroscience 2011, 125:512-518.
11. Pavlov I.P. Conditioned reflexes 1927, Oxford University Press, London.
12. Power M.L., Schulkin J. Anticipatory physiological regulation in feeding biology: cephalic phase responses. Appetite 2008, 50:194-206.
13. Powley T.L., Berthoud H.R. Diet and cephalic phase insulin responses. The American Journal of Clinical Nutrition 1985, 42:991-1002.
14. Woods S.C. The eating paradox: how we tolerate food. Psychological Review 1991, 98:488-505.
15. Woods S.C., Ramsay D.S. Pavlovian influences over food and drug intake. Behavioural Brain Research 2000, 110:175-182.
16. Berthoud H.R., Bereiter D.A., Trimble E.R., Siegel E.G., Jeanrenaud B. Cephalic phase, reflex insulin secretion. Neuroanatomical and physiological characterization. Diabetologia 1981, 20(Suppl):393-401.
17. Louis-Sylvestre J. Relationship between two stages of prandial insulin release in rats. American Journal of Physiology 1978, 235:E103-E111.
18. Tonosaki K., Hori Y., Shimizu Y. Relationships between insulin release and taste. Biomedical Research 2007, 28:79-83.
19. Tordoff M.G., Friedman M.I. Drinking saccharin increases food intake and preference - IV. Cephalic phase and metabolic factors. Appetite 1989, 12:37-56.
20. Barrera J.G., Jones K.R., Herman J.P., D'Alessio D.A., Woods S.C., Seeley R.J. Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. Journal of Neuroscience 2011, 31:3904-3913.
21. Barrera J.G., Sandoval D.A., D'Alessio D.A., Seeley R.J. GLP-1 and energy balance: an integrated model of short-term and long-term control. Nature Reviews Endocrinology 2011, 7:507-516.
22. Dossat A.M., Lilly N., Kay K., Williams D.L. Glucagon-like peptide 1 receptors in nucleus accumbens affect food intake. Journal of Neuroscience 2011, 31:14453-14457.
23. Drucker D.J. Minireview: the glucagon-like peptides. Endocrinology 2001, 142:521-527.
24. Flint A., Raben A., Astrup A., Holst J.J. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. Journal of Clinical Investigation 1998, 101:515-520.
25. Grill H.J., Hayes M.R. The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake. International Journal of Obesity (London) 2009, 33(Suppl 1):S11-S15.
26. Hayes M.R., De Jonghe B.C., Kanoski S.E. Role of the glucagon-like-peptide-1 receptor in the control of energy balance. Physiology & Behavior 2010, 100:503-510.
27. Knauf C., Cani P.D., Ait-Belgnaoui A., Benani A., Dray C., Cabou C., et al. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure. Endocrinology 2008, 149:4768-4777.
28. Punjabi M., Arnold M., Geary N., Langhans W., Pacheco-Lopez G. Peripheral glucagon-like peptide-1 (GLP-1) and satiation. Physiology & Behavior 2011, 105:71-76.
29. Rodriquez de Fonseca F., Navarro M., Alvarez E., Roncero I., Chowen J.A., Maestre O., et al. Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism 2000, 49:709-717.
30. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M., Meeran K., et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996, 379:69-72.
31. Williams D.L., Baskin D.G., Schwartz M.W. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 2009, 150:1680-1687.
32. Woods S.C., Lutz T.A., Geary N., Langhans W. Pancreatic signals controlling food intake; insulin, glucagon and amylin. Philosophical transactions of the Royal Society of London, Series B: Biological Sciences 2006, 361:1219-1235.
33. Mistlberger R.E. Circadian food-anticipatory activity: formal models and physiological mechanisms. Neuroscience and Biobehavioral Reviews 1994, 18:171-195.
34. Stephan F.K. The "other" circadian system: food as a Zeitgeber. Journal of Biological Rhythms 2002, 17:284-292.
35. Teff K.L. How neural mediation of anticipatory and compensatory insulin release helps us tolerate food. Physiology & Behavior 2011, 103:44-50.
36. Vahl T.P., Drazen D.L., Seeley R.J., D'Alessio D.A., Woods S.C. Meal-anticipatory glucagon-like peptide-1 secretion in rats. Endocrinology 2010, 151:569-575.
37. Williams D.L., Baskin D.G., Schwartz M.W. Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation. Diabetes 2006, 55:3387-3393.
38. Acitores A., Gonzalez N., Sancho V., Valverde I., Villanueva-Penacarrillo M.L. Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. The Journal of Endocrinology 2004, 180:389-398.
39. Arnes L., Gonzalez N., Tornero-Esteban P., Sancho V., Acitores A., Valverde I., et al. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. International Journal of Molecular Medicine 2008, 22:127-132.
40. D'Alessio D.A., Kahn S.E., Leusner C.R., Ensinck J.W. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. Journal of Clinical Investigation 1994, 93:2263-2266.
41. D'Alessio D.A., Prigeon R.L., Ensinck J.W. Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. A physiological role of glucagon-like peptide I. Diabetes 1995, 44:1433-1437.
42. Doyle M.E., Egan J.M. Glucagon-like peptide-1. Recent Progress in Hormone Research 2001, 56:377-399.
43. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacology & Therapeutics 2007, 113:546-593.
44. Gerspach A.C., Steinert R.E., Schonenberger L., Graber-Maier A., Beglinger C. The role of the gut sweet taste receptor in regulating GLP-1, PYY, and CCK release in humans. American Journal of Physiology, Endocrinology and Metabolism 2011, 301:E317-E325.
45. Hare K.J. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus. Danish Medical Bulletin 2010, 57:B4181.
46. Imeryuz N., Yegen B.C., Bozkurt A., Coskun T., Villanueva-Penacarrillo M.L., Ulusoy N.B. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. American Journal of Physiology 1997, 273:G920-G927.
47. Naslund E., Bogefors J., Skogar S., Gryback P., Jacobsson H., Holst J.J., et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. American Journal of Physiology 1999, 277:R910-R916.
48. Naslund E., Gutniak M., Skogar S., Rossner S., Hellstrom P.M. Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. The American Journal of Clinical Nutrition 1998, 68:525-530.
49. Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Orskov C., Ritzel R., et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. American Journal of Physiology 1997, 273:E981-E988.
50. Redondo A., Trigo M.V., Acitores A., Valverde I., Villanueva-Penacarrillo M.L. Cell signalling of the GLP-1 action in rat liver. Molecular and Cellular Endocrinology 2003, 204:43-50.
51. Sancho V., Trigo M.V., Gonzalez N., Valverde I., Malaisse W.J., Villanueva-Penacarrillo M.L. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats. Journal of Molecular Endocrinology 2005, 35:27-38.
52. Tolessa T., Gutniak M., Holst J.J., Efendic S., Hellstrom P.M. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Digestive Diseases and Sciences 1998, 43:2284-2290.
53. Villanueva-Penacarrillo M.L., Puente J., Redondo A., Clemente F., Valverde I. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models. Endocrine 2001, 15:241-248.
54. Wettergren A., Schjoldager B., Mortensen P.E., Myhre J., Christiansen J., Holst J.J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Digestive Diseases and Sciences 1993, 38:665-673.
55. Willms B., Werner J., Holst J.J., Orskov C., Creutzfeldt W., Nauck M.A. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. The Journal of Clinical Endocrinology and Metabolism 1996, 81:327-332.
56. Wishart J.M., Horowitz M., Morris H.A., Jones K.L., Nauck M.A. Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1. Peptides 1998, 19:1049-1053.
57. Wu T., Zhao B.R., Bound M.J., Checklin H.L., Bellon M., Little T.J., et al. Effects of different sweet preloads on incretin hormone secretion, gastric emptying, and postprandial glycemia in healthy humans. The American Journal of Clinical Nutrition 2012, 95:78-83.
58. Young A.A., Gedulin B.R., Rink T.J. Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 1996, 45:1-3.
59. Hare K.J., Vilsboll T., Asmar M., Deacon C.F., Knop F.K., Holst J.J. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 2010, 59:1765-1770.
60. Ford H.E., Peters V., Martin N.M., Sleeth M.L., Ghatei M.A., Frost G.S., et al. Effects of oral ingestion of sucralose on gut hormone response and appetite in healthy normal-weight subjects. European Journal of Clinical Nutrition 2011, 65:508-513.
61. Horwitz D.L., McLane M., Kobe P. Response to single dose of aspartame or saccharin by NIDDM patients. Diabetes Care 1988, 11:230-234.
62. Ma J., Bellon M., Wishart J.M., Young R., Blackshaw L.A., Jones K.L., et al. Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects. American Journal of Physiology, Gastrointestinal and Liver Physiology 2009, 296:G735-G739.
63. Ma J., Chang J., Checklin H.L., Young R.L., Jones K.L., Horowitz M., et al. Effect of the artificial sweetener, sucralose, on small intestinal glucose absorption in healthy human subjects. The British Journal of Nutrition 2010, 104:803-806.
64. Steinert R.E., Frey F., Topfer A., Drewe J., Beglinger C. Effects of carbohydrate sugars and artificial sweeteners on appetite and the secretion of gastrointestinal satiety peptides. The British Journal of Nutrition 2011, 105:1320-1328.
65. Fujita Y., Wideman R.D., Speck M., Asadi A., King D.S., Webber T.D., et al. Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo. American Journal of Physiology, Endocrinology and Metabolism 2009, 296:E473-E479.
66. Rudenga K.J., Small D.M. Amygdala response to sucrose consumption is inversely related to artificial sweetener use. Appetite 2012, 58:504-507.
67. Dhingra R., Sullivan L., Jacques P.F., Wang T.J., Fox C.S., Meigs J.B., et al. Soft drink consumption and risk of developing cardiometabolic risk factors and the metabolic syndrome in middle-aged adults in the community. Circulation 2007, 116:480-488.
68. Fowler S.P., Williams K., Resendez R.G., Hunt K.J., Hazuda H.P., Stern M.P. Fueling the obesity epidemic? Artificially sweetened beverage use and long-term weight gain. Obesity 2008, 16:1894-1900.
69. Lutsey P.L., Steffen L.M., Stevens J. Dietary intake and the development of the metabolic syndrome: the atherosclerosis risk in communities study. Circulation 2008, 117:754-761.
70. Anagnostis P., Athyros V.G., Adamidou F., Panagiotou A., Kita M., Karagiannis A., et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes, Obesity & Metabolism 2011, 13:302-312.
71. Gardener H., Rundek T., Markert M., Wright C.B., Elkind M.S., Sacco R.L. Diet soft drink consumption is associated with an increased risk of vascular events in the northern Manhattan study. Journal of General Internal Medicine: Official Journal of the Society for Research and Education in Primary Care Internal Medicine 2012, (epub ahead of print).
72. Grieve D.J., Cassidy R.S., Green B.D. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. British Journal of Pharmacology 2009, 157:1340-1351.
73. Okerson T., Chilton R.J. The cardiovascular effects of GLP-1 receptor agonists. Cardiovascular Therapeutics 2010, (epub ahead of print).
74. Aaboe K., Krarup T., Madsbad S., Holst J.J. GLP-1: physiological effects and potential therapeutic applications. Diabetes, Obesity & Metabolism 2008, 10:994-1003.
75. Jelsing J., Vrang N., Hansen G., Raun K., Tang-Christensen M., Bjerre Knudsen L. Liraglutide: short-lived effect on gastric emptying-long lasting effects on body weight. Diabetes, Obesity & Metabolism 2012, 14:531-538.
76. McGill J.B. Liraglutide: effects beyond glycaemic control in diabetes treatment. International Journal of Clinical Practice 2010, 64(Suppl):28-34.
77. Meneghini L.F., Orozco-Beltran D., Khunti K., Caputo S., Damci T., Liebl A., et al. Weight beneficial treatments for type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism 2011, 96:3337-3353.
78. Neff L.M., Kushner R.F. Emerging role of GLP-1 receptor agonists in the treatment of obesity. Diabetes, Metabolic Syndrome and Obesity 2010, 3:263-273.
79. Verges B., Bonnard C., Renard E. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system. Diabetes & Metabolism 2011, 37:477-488.
80. Vilsboll T., Christensen M., Junker A.E., Knop F.K., Gluud L.L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 2012, 344.
81. Vilsboll T., Garber A.J. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide. Diabetes, Obesity & Metabolism 2012, 14(Suppl. 2):41-49.